Browse Technologies
Browse Products
Browse Equipments
Browse Patents
*IF NO SEARCH RESULTS, YOU CAN TRY OTHER SEARCH TERMS AND RE-DO YOUR SEARCH.
OR
CREATE YOUR INFORMATION ORCONTACT US.
 
 
 
Position: Technologies --> Know-How--> Tech Opportunity
Manufacturing Mupirocin with Fermentation process

Mupirocin  is an antibiotic originally isolated from Pseudomonas fluorescens NCIMB 10586. Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations.It is used topically and effective against Gram-positive bacteria, including MRSA. Mupirocin is a mixture of several pseudomonic acids, with pseudomonic acid A (PA-A) constituting greater than 90% of the mixture. Also present in mupirocin are pseudomonic acid B with an additional hydroxyl group at C8, pseudomonic acid C with a double bond between C10 and C11, instead of the epoxide of PA-A, and pseudomonic acid D with a double bond at C4` and C5` in the 9-hydroxy-nonanoic acid portion of mupirocin.


Mupirocin has been shown to strongly inhibit protein and RNA synthesis in Staphylococcus aureus while DNA and cell wall formation were also negatively impacted a lesser degree. The inhibition of RNA synthesis was shown to be a protective mechanism in response to a lack of one amino acid, isoleucine. In vivo studies in Escherichia coli demonstrated that pseudomonic acid inhibits isoleucine t-RNA synthetase (IleRS). This mechanism of action is shared with furanomycin, an analog of isoleucine


Mupirocin is used as a topical treatment for bacterial skin infections, for example, furuncle, impetigo, open wounds etc. It is also useful in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), which is a significant cause of death in hospitalized patients who have received systemic antibiotic therapy. It is suggested, however, that mupirocin not be used for extended periods of time, or indiscriminately, as resistance does develop, and could, if it becomes widespread, destroy mupirocin's value as a treatment for MRSA. It may also result in overgrowth of non-susceptible organisms.


Technology Data:


Status: pilot                                                                                                                        


Final titre:>3g/L


Fermentation time: 60hrs


Recovery: 75-80%


Product Specification: EP or USP


Type: Batch+feeding


Main material: Glucose, Soybean meal, Glycerol, Peanut oil


Process Flowchart:


Slant---Flask---Seed Fermenter---Production Fermenter---Extraction---Resin


----Concentration-----Crystallization----Drying----finished product


 

发表时间:2008-10-31
 
Copyright 2006-2015 by Global Biologicals (G-Bio). All Rights Reserved.
京ICP备09073680号
Tel: +86-10-80748386   Cell:+86-13910029404
Email:G-Bio@FOXMAIL.COM   MSN:fujvwangsd@hotmail.com